Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

MicuRx Pharma Picks Next-Gen MRSA Antibiotic Candidate

publication date: Aug 19, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

MicuRx Pharmaceuticals, Inc., a privately held company based in the US and Shanghai, China, named its first preclinical development candidate. MicuRX is developing next-generation antibiotics aimed at multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). At the same time, the company moved into a new 10,000 square foot laboratory in ZhangJiang HighTech Park in Shanghai. The company had previously presented at the ChinaBio® Investor Forum held in Shanghai last December. More details...

Stock Symbol: (NYSE: PFE)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners